A phase Ib clinical trial of Ad-ISF35-transduced autologous cells in combination with fludarabine, cyclophosphamide, rituximab (FCR) for patients with fludarabine-refractory and/or del(17p)/p53-defective chronic lymphocytic leukemia (CLL).
J. E. Castro
No relevant relationships to disclose
L. S. Schwartzberg
No relevant relationships to disclose
J. Pinilla-Ibarz
No relevant relationships to disclose
T. J. Kipps
Stock Ownership - Memgen
M. J. Cantwell
Employment or Leadership Position - Memgen